恩替卡韦治疗46例失代偿期乙型肝炎肝硬化患者临床效果观察

doi:10.3969/j.issn.1672-5069.2016.02.025

Abstract

Zuo Linlin, Zhou Huajuan, Fang Hongju. Application of entecavir in treatment of patients with decompensated liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 217-218.

[1] 杨烨,陈景寿,欧晓娟,等.核苷类似物治疗失代偿期乙型肝炎肝硬化的随访研究.首都医科大学学报,2010,31（5）:573-577.
[2] 代雪枫,马勇,年磊等.丙氨酸氨基转移酶轻度升高慢性乙型肝炎患者肝组织病理学改变.实用肝脏病杂志,2012,15（3）:229-231.
[3] 周萍,孙慧伶,朱肖鸿,等.慢性乙型肝炎患者血清HBV DNA载量与肝组织病理学变化关系研究.实用肝脏病杂志,2014,17（4）:364-367.
[4] 王松贤.慢性乙型肝炎患者肝组织学检查的意义.实用肝脏病杂志,2014,17（3）:297-298.
[5] 张骏飞,刘波,陈从新,等.含吡咯烷生物碱的中草药致肝窦阻塞综合征研究进展.实用肝脏病杂志,2014,17（4）:445-448.
[6] 周晓玲,谢胜,侯秋科,等.脐血干细胞移植治疗失代偿期乙型肝炎肝硬化的临床研究.成都医学院学报,2013,8（5）:571-574.
[7] 许菊香,陈卫庆,陈衍秋,等.丹参酮治疗代偿期乙型肝炎肝硬化的临床疗效观察.国际流行病学传染病学杂志,2010,37（4）:248-250.
[8] 张耀武.恩替卡韦分散片联合肝爽颗粒治疗失代偿期乙型肝炎肝硬化患者临床观察.实用肝脏病杂志,2013,16（6）:550-551.
[9] 吴成久.替比夫定治疗失代偿期乙型肝炎肝硬化的疗效观察.承德医学院学报,2013,30（2）:113-114.
[10] 郑翀,黄宝如,王鹏,等.复方牛胎肝提取物联合阿德福韦酯治疗慢性乙型肝炎疗效观察.实用肝脏病杂志,2012,15（5）:404-406.
[11] 钮志林,王魏,赵刚,等.拉米夫定治疗失代偿期活动性乙型肝炎肝硬化.苏州大学学报,2006,26（3）:490-490,493.
[12] 代雪枫,齐晓林,马勇等.超声介入法治疗代偿期乙型肝炎肝硬化109例疗效分析.实用肝脏病杂志,2015,18（4）:375-378.
[13] 徐勇.替比夫定联合阿德福韦酯与恩替卡韦单药治疗失代偿期乙型肝炎肝硬化疗效比较.湖北科技学院学报,2013,14（5）:387-390.
[14] 施卫兵,杨素霞.乙型病毒性肝炎肝硬化中医证型与客观检测指标相关性.安徽中医学院学报,2009,28（4）:28-30.
[15] 马兰,高有方,王兴民,等.探讨抗病毒治疗乙型肝炎肝硬化失代的临床疗效.中国医药指南,2012,29（6）:551-552.

Application of entecavir in treatment of patients with decompensated liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[3]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[4]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[5]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[6]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[7]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[8]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[9]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[10]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[11]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[12]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[13]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[14]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[15]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.